ArticleMolecular therapy. Advances2026
Modulating viscosity improves lentiviral transduction of NK cells: A simple solution to a persistent problem.
Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genetically modified cell therapies (GMCT) hold potential for the treatment of cancer, autoimmune conditions, and rare diseases. A major determinant of GMCT success is modification efficiency, yet transducing certain cells of interest, such as primary natural killer (NK) cells, remains challenging. Major barriers to widespread adoption of GMCT are cost and difficulty of scale. Therefore, improving transduction rates with accessible, good manufacturing practices (GMP) compatible reagents may help reduce this barrier and prevent manufacturing failure. We show that using a modified viscous transduction medium (VTM) made with methyl-cellulose significantly increased the transduction efficiency of primary human NK cells without affecting viability, expansion, or function. VTM outperformed commercially available transduction enhancers. Transduction with VTM significantly improved the yield of anti-CD22 chimeric antigen receptor (CAR)-NK cells. Moreover, VTM was similarly effective at improving the transduction of primary T cells and hematopoietic stem cells. Overall, VTM may provide a simple, cost-effective, and GMP-compliant solution to increase the yield of genetically modified immune cells for immunotherapy. This may improve the efficacy of immunotherapies and reduce the overall costs of production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.